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Background: A risk treatment (RT) paradox is prevalent in NSTE-ACS; wherein high risk patients are least likely to receive evidence based care. The 
influence of sex on RT paradox is unclear. Accordingly, we evaluated this issue across sex within a registry of NSTE-ACS patients.
methods: Two cohorts of NST-ACS (n=552) were studied (Sept-Nov2008 & Mar-Jun2010) comparing sex and accounting for GRACE risk score, 
biomarker + and prior REVASC.
results: Selected characteristics, in-hospital care, clinical events and medications are shown in table. Despite similar times of presentation 
(males (M) 2.0 vs. females (F) 1.9 hrs, p=0.5) F had delayed admission to CCU (M 11.9 vs. F 15.1 hours, p<0.001). RT paradox existed in F with 
GRACE >140: CATH M 57.3% vs F 43.1% (p=0.057) and REVASC M 42.7% vs F 29.2% (p=0.061). Troponin + M had higher CATH 81.5% vs 66.7% 
(p=0.0012) and REVASC 65.1% vs 38.3% (p<0.001). With no prior REVASC, M more likely had CATH: 84.6% vs 68.9%, p<0.001. GRACE score 
adjusted death/re-MI/HF/shock was increased in F OR 2.04 (1.17-3.57). In contrast in all that had CATH, GRACE adjusted events were lower in F OR 
0.60 (0.37-0.95).
conclusion: F represent 30% of NSTE-ACS are older, higher risk but are less likely to undergo CATH/ REVASC and receive evidence based 
medications with more events. The RT paradox persist with GRACE risk >140, + troponin, and without prior REVASC. The RT paradox in NST-ACS is 
more prevalent in F and represents an unmet need that should be further investigated and addressed in clinical practice. 
All (n = 552) Men (n = 386) Women (n = 166) p
EMS presentation 36.2% 30.0% 50.6% <0.001
Age (y), median (q1, q3) 67 (56, 78) 64 (54, 75) 75 (62, 82) <0.001
Prior revascularization 22.8% 25.1% 17.5% 0.14
Calculated creatinine clearance Initial 75.7 (45.7, 104.3) 85.6(57.9, 113.0) 44.7(32.5, 75.7) <0.001
Killip class >2 6.9% 6.5% 7.8% 0.63
GRACE Risk Score, >140 34.2% 30.3% 43.4% 0.011
Baseline troponin I (≥0.15 µg/L) 73.8% 74.3% 72.7% 0.69
Length of stay (days (q1,q3)) 5.5 (3.7,10.1) 5.1 (3.5,9.9) 5.9 (4.0,10.4) 0.09
Catheterization rate 77.7% 81.3% 69.3% 0.0018
Revascularization rate 56.0% 62.4% 41.0% <0.001
Repeat-MI 1.6% 0.8% 3.6% 0.016
Congestive Heart Failure 6.2% 4.4% 10.2% 0.0089
Death 3.1% 2.6% 4.2% 0.3105
ASA (discharge) 90.2% 93.3% 83.1% <0.001
Clopidogrel (discharge) 66.7% 69.4% 60.2% 0.092
ACE-inhibitor 69.0% 73.8% 57.8% <0.001
B-Blocker 83.5% 84.7% 80.7% 0.40
Statins 87.0% 88.3% 83.7% 0.30
